Drug Information

Drug (ID: DG01815) and It's Reported Resistant Information

• Name: 5-Ethynyl-2'-deoxyuridine
• Synonyms: 5-Ethynyl-2'-deoxyuridine; 61135-33-9; 2'-Deoxy-5-ethynyluridine; 5-Ethynyl-2'-dU; Uridine, 2'-deoxy-5-ethynyl-; UNII-G373S00W2J; EdU (5-ethynyl-2'-deoxyuridine); G373S00W2J; MFCD01675687; 5-ethynyl-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 5'-Ethynyl-2'-deoxyuridine; 5-Ethynyl-dUrd; 5-ethynyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; 5-Ethynyl-dU; EDU; BRN 0756841; 5-EdU; 2'deoxy-5-ethynyluridine; EdU (ethynyldeoxyuridine); SCHEMBL868882; CHEMBL222932; DTXSID20976652; ZINC3794605; s1661; AKOS024462948; 5-Ethynyl-2'-deoxy-uridine (5-EdU); AC-32360; AS-59368; HY-118411; CS-0065850; C75857; 5-Ethynyl-2'-deoxyuridine, (EdU), AldrichCPR; J-700091; J-700347; Q4639590; 1-(2-Deoxypentofuranosyl)-5-ethynyl-4-hydroxypyrimidin-2(1H)-one; 5-ethynyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione; 5-ethynyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Breast cancer [ICD-11: 2C60]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 3
• IsoSMILES: C#CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O
• InChI: InChI=1S/C11H12N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h1,4,7-9,14-15H,3,5H2,(H,12,16,17)/t7-,8+,9+/m0/s1
• InChIKey: CDEURGJCGCHYFH-DJLDLDEBSA-N
• PubChem CID: 472172

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Breast cancer [ICD-11: 2C60]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Nuclear paraspeckle assembly transcript 1 (NEAT1) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Breast adenocarcinoma [ICD-11: 2C60.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• In Vitro Model: MDA-MB-468 cells; Breast; Homo sapiens (Human); CVCL_0419
• In Vitro Model: BT-549 cells; Breast; Homo sapiens (Human); CVCL_1092
• In Vitro Model: MF-7 cells; N.A.; .; N.A.
• Experiment for Molecule Alteration: Western bloting analysis; qRT-PCR; Overexpression assay
• Experiment for Drug Resistance: EdU assay
• Mechanism Description: Identification of LncRNA NEAT1/miR-21/RRM2 axis as a novel biomarker in breast cancer.

References

• Ref 1: NEAT1 regulates MPP(+)-induced neuronal injury by targeting miR-124 in neuroblastoma cellsNeurosci Lett. 2019 Aug 24;708:134340. doi: 10.1016/j.neulet.2019.134340. Epub 2019 Jun 19.